Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: Data of a prematurely stopped clinical trial

G. J. Timmers, S. Zweegman, A. M. Simoons-Smit, A. C. Van Loenen, D. Touw, P. C. Huijgens

Research output: Contribution to journalArticleAcademicpeer-review

61 Citations (Scopus)


We conducted an open label, randomised clinical trial to compare amphotericin B colloidal dispersion (ABCD, Amphocil) 2 mg/kg/day intravenously with fluconazole 200 mg/day orally, for the prevention of fungal disease in neutropenic patients with haematological malignancies. In the event of unresolved fever after 4 days of empirical antibacterial therapy, patients in both treatment groups were to receive ABCD, 4 mg/kg/day. However, the study had to be stopped in an early phase, due to severe side-effects of ABCD. A total of 24 patients were enrolled, 12 patients were randomly assigned to receive prophylactic ABCD, which was administered for a mean of 13.9 days. Fluconazole prophylaxis was given to 12 patients for a mean of 21.2 days. Therapeutic ABCD, 4 mg/kg, was initiated in four patients because of suspected fungal infection, all of whom had initially received fluconazole. A high rate of infusion-related toxicity of ABCD was observed. Chills occurred in 15/16 ABCD recipients (94%), accompanied by a temperature rise of >/=2 degrees C in 4/16 patients and of >/=1 degrees C but
Original languageEnglish
Pages (from-to)879-884
Number of pages6
JournalBone marrow transplantation
Issue number8
Publication statusPublished - 2000


  • ABCD
  • Amphocil
  • Neutropenia
  • Prophylaxis
  • Toxicity

Cite this